ReviewResearch and practice in thrombosis and haemostasis2020
Essential aspects of the follow-up after acute pulmonary embolism: An illustrated review.
Review in Research and practice in thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Catheter-directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism.The Cochrane database of systematic reviews · 2022Pooled it
- How I treat pediatric pulmonary embolism.Blood · 2025Review
- Practical guide to management after an acute pulmonary embolism.BMJ open respiratory research · 2025Review
- Knowledge, Attitudes, and Practices Among Thoracic Healthcare Professionals Toward Postoperative Pulmonary Embolism.Healthcare (Basel, Switzerland) · 2025Article
- Article
- Acute Pulmonary Embolism: Evidence, Innovation, and Horizons.Current cardiology reports · 2024Review
- Association between pre-treatment computed tomography findings and post-treatment persistent decrease in lung perfusion blood volume.Scientific reports · 2024Article
- Multimodality imaging of acute and chronic pulmonary thromboembolic disease.Breathe (Sheffield, England) · 2024Review
- Catheter Interventions for Pulmonary Embolism: Mechanical Thrombectomy Versus Thrombolytics.Methodist DeBakey cardiovascular journal · 2024Review
- The Journey to a Successful Illustrated Review.Research and practice in thrombosis and haemostasis · 2022Review
- ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly.ERJ open research · 2022Review
- Article
- Role of von Willebrand factor in venous thromboembolic disease.JVS-vascular science · 2022Review
- Prophylaxis and treatment of COVID-19 related venous thromboembolism.Postgraduate medicine · 2021Review
- A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension.ERJ open research · 2021Article
- Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin.Research and practice in thrombosis and haemostasis · 2021Article
- Caging the dragon: Research approach to COVID-19-related thrombosis.Research and practice in thrombosis and haemostasis · 2021Review
- Essential aspects of the follow-up after acute pulmonary embolism: An illustrated review.Research and practice in thrombosis and haemostasis · 2020Review
- Value of Optimal Follow-up in Patients with Pulmonary Embolism (OFUPE): Study Protocol for a Prospective Randomized Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Care for patients with acute pulmonary embolism (PE) involves more than determination of the duration of anticoagulant therapy. After choosing the optimal initial management strategy based on modern risk stratification schemes, patients require focused attention aimed at prevention of major bleeding, identification of underlying (malignant) disease, prevention of cardiovascular disease, and monitoring for long-term complications. The most frequent complication of PE is the so-called "post-PE syndrome," a phenomenon of permanent functional limitations after PE occurring in up to 50% of patients. The post-PE syndrome is caused by persistent deconditioning, anxiety, and/or ventilatory or circulatory impairment as a result of acute PE. The most severe and most feared presentation of the post-PE syndrome is chronic thromboembolic pulmonary hypertension (CTEPH), a deadly disease if it remains untreated. While CTEPH may be successfully treated with pulmonary endarterectomy, balloon pulmonary angioplasty, and/or pulmonary hypertension drugs, the major challenge is to diagnose CTEPH at an early stage. Poor awareness for the post-PE syndrome and in particular for CTEPH, high prevalence of persistent symptoms after PE and inefficient application of diagnostic tests in clinical practice all contribute to an unacceptable diagnostic delay and underdiagnosis. Its consequences are dire: increased mortality in patients with CTEPH, and excess health care costs, higher prevalence of depression, more unemployment and poorer quality of life in patients with post-PE syndrome in general. In this review, we provide an overview of the incidence and impact of the post-PE syndrome, and illustrate the clinical presentation, optimal diagnostic strategy as well as therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.